Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Bcr-Abl inhibitors target the constitutively active fusion tyrosine kinase encoded by the Philadelphia chromosome. The translocation joins the breakpoint cluster region (BCR) gene to the Abelson tyrosine kinase gene (ABL1) on chromosome 22. Expression of the P210 form of Bcr-Abl in mouse bone marrow cells induced a disease resembling chronic myelogenous leukemia (CML) in 1990. In 1996 imatinib (CGP 57148), listed here as the base and as imatinib mesylate, was reported to inhibit Abl and Bcr-Abl-positive cell growth. Dasatinib, described in 2004, also inhibits Src family kinases and blocks many imatinib-resistant Abl mutants. Nilotinib and bafetinib are further Abl inhibitors, and ponatinib also inhibits the T315I gatekeeper mutant.
Phe-PEG1-Dasa is a BCR-ABL PROTAC degrader, demonstrating a DC50 value of 1.56 nM. This compound utilizes phenylalanine as the E3 ligase ligand and triggers the N-end rule pathway to facilitate the degradation of target proteins. Phe-PEG1-Dasa effectively suppresses the proliferation of K562 leukemia cells, making it a valuable tool for research into leukemia treatment strategies.
Out of stock
All 3 sizes
PonatiLink-1-24 is an inhibitor of the Abelson murine leukemia virus (ABL) enzyme. This compound demonstrates significant biological activity by selectively inhibiting ABL kinase activity, which is vital in various malignancies. It is particularly useful in studying cancer cell signaling pathways and the development of targeted therapies for ABL-related disorders.
Out of stock
All 3 sizes
AP-24226 is a selective inhibitor of the non-receptor tyrosine kinases Src and ABL. It exhibits significant activity in hindering cell proliferation and survival in various cancer cell lines, making it a valuable tool for cancer research. Its specificity for Src/ABL pathways allows for detailed investigations into their roles in oncogenic processes and therapeutic responses.
Tyrosine kinase-IN-9 is a potent inhibitor of the c-Abl tyrosine kinase. This compound demonstrates significant biological activity in modulating signaling pathways associated with neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. It serves as a valuable research tool for investigating the roles of c-Abl in cellular processes related to these conditions.
BCR-ABL kinase-IN-3 is a potent inhibitor of the BCR-ABL fusion protein, a critical driver in the pathology of acute myeloid leukemia (AML). This compound exhibits significant biological activity in inhibiting the kinase activity, making it a valuable tool for research into therapeutic strategies targeting BCR-ABL-related malignancies. Its application spans the investigation of molecular mechanisms underlying leukemia and the development of innovative treatments for improved patient outcomes.
BCR-ABL-IN-11 is a selective BCR-ABL inhibitor that exhibits significant anticancer activity in chronic myelogenous leukemia (CML) models. With an IC50 value of 129.61 μM in K562 cells, BCR-ABL-IN-11 is a useful tool for studying the molecular mechanisms underlying CML and for evaluating potential therapeutic strategies targeting this oncogenic fusion protein. Its efficacy makes it suitable for research applications focused on leukemia treatment and drug resistance mechanisms.
Out of stock
All 3 sizes
SNIPER(ABL)-020 is a PROTAC compound designed to selectively degrade the BCR-ABL fusion protein through targeted ubiquitin-proteasome pathway engagement. By conjugating Dasatinib, an ABL inhibitor, with Bestatin, an IAP ligand, SNIPER(ABL)-020 effectively promotes the protein's ubiquitination and subsequent degradation. This reagent is valuable for research focused on chronic myeloid leukemia and BCR-ABL related signaling pathways, offering insights into targeted protein degradation mechanisms in cancer therapeutics.
